Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTXFree Report) in a research report released on Monday, Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.

Separately, Cantor Fitzgerald reaffirmed an overweight rating and issued a $6.00 target price on shares of Lineage Cell Therapeutics in a report on Monday, February 5th.

Read Our Latest Analysis on Lineage Cell Therapeutics

Lineage Cell Therapeutics Stock Performance

Shares of LCTX opened at $1.16 on Monday. The firm has a market cap of $219.01 million, a P/E ratio of -8.92 and a beta of 1.39. Lineage Cell Therapeutics has a 1-year low of $0.84 and a 1-year high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTXGet Free Report) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. The firm had revenue of $2.09 million for the quarter, compared to analyst estimates of $4.74 million. Lineage Cell Therapeutics had a negative return on equity of 31.95% and a negative net margin of 240.20%. On average, analysts predict that Lineage Cell Therapeutics will post -0.13 earnings per share for the current year.

Institutional Trading of Lineage Cell Therapeutics

Several hedge funds have recently bought and sold shares of LCTX. Rathbones Group PLC purchased a new position in shares of Lineage Cell Therapeutics in the 3rd quarter worth approximately $41,000. SG Americas Securities LLC lifted its stake in Lineage Cell Therapeutics by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock valued at $34,000 after purchasing an additional 11,779 shares during the last quarter. DCF Advisers LLC increased its position in Lineage Cell Therapeutics by 14.5% in the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock worth $103,000 after buying an additional 12,000 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC bought a new stake in shares of Lineage Cell Therapeutics in the first quarter valued at $30,000. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

(Get Free Report)

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Featured Articles

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with's FREE daily email newsletter.